Advances in Therapy

, 25:627

DPP4 Inhibitors: a new approach in diabetes treatment

Review
  • 494 Downloads

Abstract

The role of dipeptidyl peptidase-IV (DPP4) as both a regulatory enzyme and a signalling factor has been evaluated and described in many studies. DPP4 inhibition results in increased blood concentration of the incretin hormones glucagon-like peptide-1 (GLP-1) and gastric inhibitory polypeptide (GIP). This causes an increase in glucose-dependent stimulation of insulin secretion, resulting in a lowering of blood glucose levels. Recent studies have shown that DPP4 inhibitors can induce a significant reduction in glycosylated haemoglobin (HbA1c) levels, either as monotherapy or as a combination with other antidiabetic agents. Research has also demonstrated that DPP4 inhibitors portray a very low risk of hypoglycaemia development. This review article focuses on the two leading agents of this category (sitagliptin and vildagliptin), providing an overview of their function along with the latest data regarding their clinical efficacy as antidiabetic agents.

Keywords

diabetes dipeptidyl peptidase-IV DPP4 sitagliptin vildagliptin 

References

  1. 1.
    CDC web site. Diabetes and gestational diabetes trends among adults in the United States. Available at: www.cdc.gov., Accessed June 2008.Google Scholar
  2. 2.
    Zinman B. Translating the Diabetes Control and Complications Trial (DCCT) into clinical practice: overcoming the barriers. Diabetologia. 1997;40(suppl 2):S88–S90.CrossRefGoogle Scholar
  3. 3.
    Elrick H, Stimmler L, Hlad CJ Jr, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab. 1964;24:1076–1082.PubMedGoogle Scholar
  4. 4.
    Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J Clin Invest. 1967;46:1954–1962.PubMedGoogle Scholar
  5. 5.
    Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care. 2003;26:2929–2940.PubMedCrossRefGoogle Scholar
  6. 6.
    Vilsboll T, Holst JJ. Incretins, insulin secretion and type-2 diabetes mellitus. Diabetologia. 2004;47:357–366.PubMedCrossRefGoogle Scholar
  7. 7.
    Xu G, Stoffers DA, Habener JF, et al. Exendin 4 stimulates both b-cell replication and neogenesis, resulting in increased b-cell mass and improved glucose tolerance in diabetic rats. Diabetes. 1999;48:2270–2276.PubMedCrossRefGoogle Scholar
  8. 8.
    Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology. 2002;143:4397–4408.PubMedCrossRefGoogle Scholar
  9. 9.
    Perfetti R, Hui H. The role of GLP-1 in the life and death of pancreatic beta cells. Horm Metab Res. 2004;36:804–810.PubMedCrossRefGoogle Scholar
  10. 10.
    Nauck M, Stockmann F, Ebert R, et al. Reduced incretin effect in type 2 (noninsulin-dependent) diabetes. Diabetologia. 1986;29:46–52.PubMedCrossRefGoogle Scholar
  11. 11.
    Drucker DJ, Philippe J, Mojsov S, et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci U S A. 1987;84:3434–3438.PubMedCrossRefGoogle Scholar
  12. 12.
    Ahren B. DPP-4 inhibitors. Best Pract Res Clin Endocrinol Metab. 2007;21:517–533.PubMedCrossRefGoogle Scholar
  13. 13.
    Nystrom T, Gutniak M, Zhang Q, et al. Effects of glucagon-like peptide-1 on endothelial function in type-2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287:E1209–E1215.PubMedCrossRefGoogle Scholar
  14. 14.
    Qi SY, Riviere PJ, Trojnar J, et al. Cloning and characterization of dipeptidyl peptidase 10, a new member of an emerging subgroup of serine proteases. Biochem J. 2003;373:179–189.PubMedCrossRefGoogle Scholar
  15. 15.
    Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368:1696–1705.PubMedCrossRefGoogle Scholar
  16. 16.
    Deacon CF. Dipeptidyl peptidase 4 inhibition with sitagliptin: a new therapy for type 2 diabetes. Expert Opin Investig Drugs. 2007;16:533–545.PubMedCrossRefGoogle Scholar
  17. 17.
    Byettal (exenatide) [package insert]. San Diego, CA: Amylin Pharmaceuticals; 2007.Google Scholar
  18. 18.
    Barnett A. Exenatide. Expert Opin Pharmacother. 2007;8:2593–2608.PubMedCrossRefGoogle Scholar
  19. 19.
    Mikhail N. Exenatide: a novel approach for treatment of type 2 diabetes. South Med J. 2006;99:1271–1279.PubMedGoogle Scholar
  20. 20.
    Lambeir AM, Durinx C, Scharpe S, et al. Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. Crit Rev Clin Lab Sci. 2003;40:209–294.PubMedCrossRefGoogle Scholar
  21. 21.
    Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept. 1999;85:9–24.PubMedCrossRefGoogle Scholar
  22. 22.
    Mentlein R, Gallwitz B, Schmidt WE. Dipeptidyl peptidase IV, hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem. 1993;214:829–835.PubMedCrossRefGoogle Scholar
  23. 23.
    Deacon CF, Johnson AH, Holst JJ. Degradation of glucagon-like hydrolyzes substance peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab. 1995;80:952–957.PubMedCrossRefGoogle Scholar
  24. 24.
    Deacon CF, Nauck MA, Toft-Nielsen M, et al. Both subcutaneously and intravenously administered glucagon like peptide I are rapidly degraded from the NH2-terminus in type II diabetic patients and in healthy subjects. Diabetes. 1995;44:1126–1131.PubMedCrossRefGoogle Scholar
  25. 25.
    Deacon CF, Pridal L, Klarskov L, et al. Glucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig. Am J Physiol. 1996;271:E458–464.PubMedGoogle Scholar
  26. 26.
    Kieffer TJ, McIntosh CHS, Pederson RA. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology. 1995;136:3585–3596.PubMedCrossRefGoogle Scholar
  27. 27.
    Pauly RP, Rosche F, Wermann, et al. Biological Demuth H-U. Investigation of glucose-dependent insulinotropic polypeptide-(1–42) and glucagon-like peptide-1-(3–36) degradation in vitro by dipeptidyl peptidase IV using matrixassisted Laser desorption/ionization-time of flight mass spectrometry. J Biol Chem. 1996;271:23222–23229PubMedCrossRefGoogle Scholar
  28. 28.
    Siegel EG, Gallwitz B, Scharf G, et al. Biological activity of GLP-1-analogues with N-terminal modifications. Regul Pept. 1999;79:93–102.PubMedCrossRefGoogle Scholar
  29. 29.
    Hupe-Sodmann K, McGregor GP, Bridenbaugh R, et al. Characterisation of the processing by human neutral endopeptidase 24.11 of GLP-1(7–36)amide and comparison of the substrate specificity of the enzyme for other glucagon-like peptides. Regul Pept. 1995;58:149–156.PubMedCrossRefGoogle Scholar
  30. 30.
    Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract. 2006;60:1454–1470.PubMedCrossRefGoogle Scholar
  31. 31.
    Villhauer EB, Brinkman JA, Naderi GB, et al. 1-[[(3-hydroxy-1-adamantyl) amino-]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycaemic properties. J Med Chem. 2003;46:2774–2789.PubMedCrossRefGoogle Scholar
  32. 32.
    Augeri DJ, Robl JA, Betebenner DA, et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:5025–5037.PubMedCrossRefGoogle Scholar
  33. 33.
    Kim D, Wang L, Beconi M, et al. (2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-rifluorophenyl) butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem. 2005;48:141–151.PubMedCrossRefGoogle Scholar
  34. 34.
    Mu J, Woods J, Zhou YP, et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes. 2006;55:1695–1704.PubMedCrossRefGoogle Scholar
  35. 35.
    Ahren B, Sorhede Winzell M, Burkey B, et al. Beta-cell expression of a dominantnegative HNF-1 alpha compromises the ability of inhibition of dipeptidyl peptidase-4 to elicit a long-term augmentation of insulin secretion in mice. Eur J Pharmacol. 2005;521:164–168.PubMedCrossRefGoogle Scholar
  36. 36.
    He YL, Sabo R, Campestrini J, et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase IV (DPP-4) inhibitor vildagliptin. Eur J Clin Pharmacol. 2007;63:677–686.PubMedCrossRefGoogle Scholar
  37. 37.
    Herman GA, Bergman A, Liu F, et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol. 2006;46:876–886.PubMedCrossRefGoogle Scholar
  38. 38.
    Ahren B, Gomis R, Standl E, et al. Twelve and 52-week efficacy of the dipeptidyl peptidase IV LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2874–2880.PubMedCrossRefGoogle Scholar
  39. 39.
    Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomised, placebo-controlled study in healthy male volunteers. Clin Ther. 2006;28:55–72.PubMedCrossRefGoogle Scholar
  40. 40.
    He YL, Sadler BM, Sabo R, et al. The absolute oral bioavailability and populationbased pharmacokinetic modelling of a novel dipeptidyl peptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787–802.PubMedCrossRefGoogle Scholar
  41. 41.
    Hanefeld M, Herman GA, Wu M, et al. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. Curr Med Res Opin. 2007;23:1329–1339.PubMedCrossRefGoogle Scholar
  42. 42.
    Gallwitz B. Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes. Drugs Today (Barc). 2007;43:801–814.Google Scholar
  43. 43.
    Miller S, St Onge EL. Sitagliptin: a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. Ann Pharmacother. 2006;40:1336–1343.PubMedCrossRefGoogle Scholar
  44. 44.
    Herman GA, Bergmann J, Wagner JA. Sitagliptin, a DPP-4 inhibitor: an overview of the pharmacokinetic (PK) profile and the propensity for drug-drug interactions (DDI). Diabetologia. 2006;49:481.CrossRefGoogle Scholar
  45. 45.
    Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin. 2006;22:1939–1947.PubMedCrossRefGoogle Scholar
  46. 46.
    Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycaemic control in patients with type 2 diabetes. Diabetes Care. 2007;30:1979–1987.PubMedCrossRefGoogle Scholar
  47. 47.
    Miller JL, Migoya E, Talaty JE. The effect of MK-0431 on the pharmacokinetics of digoxin after concomitant administration for 10 days in healthy subjects. Clin Pharmacol Ther. 2006;79:24.CrossRefGoogle Scholar
  48. 48.
    He Y-L, Wang Y, Bullock JM, et al. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. J Clin Pharmacol. 2007;47:633–641.PubMedCrossRefGoogle Scholar
  49. 49.
    He YL, Sabo R, Balez S, et al. The absolute oral bioavailability and populationbased pharmacokinetic modelling of a novel dipeptidyl peptidase-IV inhibitor, vildagliptin, in healthy volunteers. Clin Pharmacokinet. 2007;46:787–802.PubMedCrossRefGoogle Scholar
  50. 50.
    Barilla D, He Y, Balez S, et al. No pharmacokinetic interactions or acute clinical safety issues preclude combination of the DPP-4 inhibitor LAF237 with glyburide. Diabetes. 2004;53(suppl 2):470.Google Scholar
  51. 51.
    He YL, Sabo R, Picard F, et al. Lack of pharmacokinetic interaction between vildagliptin and metformin in patients with type 2 diabetes. Clin Pharmacol Ther. 2006;79:62.CrossRefGoogle Scholar
  52. 52.
    Serra DB, He YL, Wang Y, et al. Combination of the DPP-4 inhibitor vildagliptin (LAF237) with pioglitazone is safe and well tolerated with no pharmacokinetic interaction. Diabetes. 2005;54(suppl 1):528–529.Google Scholar
  53. 53.
    Hanefeld M, Herman G, Mickel C, et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycaemic control after 12 weeks in patients with type-2 diabetes. Diabetologia. 2005;49 (suppl 1):A287.Google Scholar
  54. 54.
    Scott R, Wu L, Sanchez M, et al. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type-2 diabetes. Int J Clin Pract. 2007;61:171–180.PubMedCrossRefGoogle Scholar
  55. 55.
    Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycaemic control in patients with type-2 diabetes. Diabetes Care. 2006;29:2632–2637.PubMedCrossRefGoogle Scholar
  56. 56.
    Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type-2 diabetes mellitus. Diabetologia. 2006;49:2564–2571.PubMedCrossRefGoogle Scholar
  57. 57.
    Rosenstock J, Baron MA, Dejager S, et al. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomised trial. Diabetes Care. 2007;30:217–223.PubMedCrossRefGoogle Scholar
  58. 58.
    Schweizer A, Couturier A, Foley JE, et al. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. Diabet Med. 2007;24:955–961.PubMedCrossRefGoogle Scholar
  59. 59.
    Ahren B, Landin-Olsson M, Jansson PA, et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels and reduces glucagon levels in type-2 diabetes. J Clin Endocrinol Metab. 2004;89:2078–2084.PubMedCrossRefGoogle Scholar
  60. 60.
    Ristic S, Byiers S, Foley J, et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin (LAF237) dose response. Diabetes Obes Metab. 2005;7:692–698.PubMedCrossRefGoogle Scholar
  61. 61.
    Pi-Sunyer FX, Schweizer A, Mills D, et al. Efficacy and tolerability of vildagliptin monotherapy in drug-naïve patients with type-2 diabetes. Diabetes Res Clin Pract. 2007;76:132–138.PubMedCrossRefGoogle Scholar
  62. 62.
    Scherbaum WA, Schweizer A, Mari A, et al. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia. Diabetes Obes Metab. 2008;Feb 1 [Epub ahead of print].Google Scholar
  63. 63.
    Brazg R, Xu L, Dalla Man C, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin of 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab. 2007;9:186–193.PubMedCrossRefGoogle Scholar
  64. 64.
    Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care. 2006;29:2638–2643.PubMedCrossRefGoogle Scholar
  65. 65.
    Rosenstock J, Brazg R, Andryuk PJ, et al. Sitagliptin Study 019 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomised, doubleblind, placebo-controlled, parallel-group study. Clin Ther. 2006;28:1556–1568.PubMedCrossRefGoogle Scholar
  66. 66.
    Jago C. American Diabetes Association. Updates on drug treatments-66th Scientific Sessions 9–13 June 2006, Washington, DC, USA. IDrugs. 2006;9:538–541.PubMedGoogle Scholar
  67. 67.
    Hermansen K, Kipnes M, Luo E, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab. 2007;9:733–745.PubMedCrossRefGoogle Scholar
  68. 68.
    Ahren B, Pacini G, Foley JE, et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type-2 diabetes over 1 year. Diabetes Care. 2005;28:1936–1940.PubMedCrossRefGoogle Scholar
  69. 69.
    Balas B, Baig MR, Watson C, et al. The dipeptidyl peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. J Clin Endocrinol Metab. 2007;92:1249–1255.PubMedCrossRefGoogle Scholar
  70. 70.
    Garber AJ, Schweizer A, Baron MA, et al. Vildagliptin in combination with pioglitazeone improves glycaemic control in patients with type-2 diabetes failing thiazolidinedione monotherapy: a randomised, placebo-controlled study. Diab Obes Metab. 2007;9:166–174.CrossRefGoogle Scholar
  71. 71.
    Rosenstock J, Baron MA, Camisasca RP, Couturier A et, al. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. Diab Obes Metab. 2007;9:175–185.CrossRefGoogle Scholar
  72. 72.
    Garber AJ, Foley JE, Banerji MA, et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab. 2008; Feb 18 [Epub ahead of print].Google Scholar
  73. 73.
    Fonseca V, Schweizer A, Albrecht D, et al. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50:1148–1155.PubMedCrossRefGoogle Scholar
  74. 74.
    Janumet (exenatide) [package insert]. Whitehouse Station, NJ: Merck & Co; 2008.Google Scholar

Copyright information

© Springer Healthcare Communications 2008

Authors and Affiliations

  1. 1.Harvard Medical SchoolJoslin Diabetes CenterBostonUSA
  2. 2.Harvard Medical SchoolResearch Director, Microcirculation Lab, and Joslin-Beth Israel Deaconess Foot CenterBostonUSA
  3. 3.Microcirculation Lab, Palmer 317Beth Israel Deaconess Medical CenterBostonUSA

Personalised recommendations